^
    Back
    Association details:
    Biomarker:CD38 expression
    Cancer:Multiple Myeloma
    Drug:STI-6129 (Microtubule inhibitor, CD38-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    AACR-II 2020
    Title:

    Abstract LB-227: Preclinical development and characterization of STI-6129, an anti-CD38 antibody-drug conjugate, as a new therapeutic agent for multiple myeloma

    Published date:
    05/15/2020
    Excerpt:
    STI-6129 exhibits potent in vitro and in vivo anti-tumor activities in multiple CD38-positive hematological models. 
    DOI:
    10.1158/1538-7445.AM2020-LB-227